Efficacy of adhesive strength of new hydrogel formulation

  • Research type

    Research Study

  • Full title

    Evaluation of the adhesive strength of the geko™ X-T3 neuromuscular stimulator incorporating a new skin adhesive hydrogel formulation designated KM40C

  • IRAS ID

    281585

  • Contact name

    Indira Natarajan

  • Contact email

    Indira.Natarajan@uhnm.nhs.uk

  • Sponsor organisation

    Firstkind Ltd

  • Clinicaltrials.gov Identifier

    NCT04309110

  • Duration of Study in the UK

    0 years, 9 months, 1 days

  • Research summary

    The study will look at the stickiness of a new skin adhesive incorporated into a new next generation geko™ device called the geko™ X-T3 and compare it to the adhesive currently used into the geko™ T3 device. Both the geko™ T3 and XT-3 are self adhesive medical devices. They are about the size of a wrist watch and attach to the side of the knee. When switched on, gentle painless electrical pulses are produced which contract the calf muscles and increase blood flow to the lower leg. The study is for people who are in hospital in the Acute Stroke Unit, and who will be receiving daily treatment with the geko™ T3 device in line with UK guidelines as part of their standard acute stroke care and venous thromboembolism prevention. The only difference between the currently used geko™ T3 device and the new geko™ XT-3 device is the adhesive used to attach each device to the skin. Both devices are Œ marked for the purpose they are being used for in the study therefore there will be no differences in the standard of acute stroke care patients receive. By taking part in the study patients will be helping to determine whether the new geko™ XT-3 device will be a suitable replacement for the geko™ T3 device.

  • REC name

    South West - Cornwall & Plymouth Research Ethics Committee

  • REC reference

    20/SW/0114

  • Date of REC Opinion

    4 Aug 2020

  • REC opinion

    Unfavourable Opinion